Fate Therapeutics, Inc.

NASDAQ:FATE

Biotechnology

Healthcare
$1.02 -0.00%

-$0.00 today

Market cap
$118.89M
Beta
2.52
P/E (TTM)
-1.8
EPS (TTM)
-$1.08
52W Low $0.91High $2.88

Volume 2.43M

Average 2.92M

FATE Operating Margin

Operating income as a percentage of revenue, showing the profitability of core operations.

Fate Therapeutics, Inc.NASDAQ: FATE

Operating Margin · Q1 FY2026 · quarter ended Mar 2026

Operating margin narrows to -2540.4%

Operating margin was -2540.4% in Q1 FY2026, down 6.3 pp from a year earlier. On a trailing-twelve-month basis it was -2207.5%, down 704.0 pp year over year. Over 3 fiscal years it narrowed by 1902.2 pp.

Context

  • Operating margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

What to watch

Whether operating margin reaches the consensus estimate from 6 analysts of -2082.1% for the fiscal year ending Dec 2026, up from -2222.4% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-2540.4%-4.2 pp QoQ
Last fiscal yearDec 2025
-2222.4%-679.8 pp YoY
LTMMar 2026
-2207.5%-704.0 pp YoY
Operating Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-6.3 pp-527.5 pp-521.1 pp
1 year-679.8 pp+140.3 pp+820.1 pp
3 years-1902.2 pp-3146.9 pp-1244.7 pp
5 years+2133.1 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Margin history

Percent of revenue · from the income statement

Latest · FY2025
-2222.4%
Year-over-year change
-679.8pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Margin vs competitors

How FATE compares with its peers on the latest reported figures

  • FATE's LTM Mar 2026 operating margin of -2207.5% is the 3rd highest of the 4 companies compared; the peer median is -741.3%.
  • Its year-over-year change of -704.0 pp is the 3rd highest of 4, against a peer median of -576.1 pp.
  • Over three fiscal years its change of -1902.2 pp compares with a peer median of -65426.8 pp.
FATE Competitors Peer median
Operating Margin for FATE and competitors
Company Period LTM level YoY 3-year change
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026-503.2% +1496.5 pp—
ALECAlector, Inc.LTM Mar 2026-741.3% -576.1 pp-589.7 pp
FATEFate Therapeutics, Inc.LTM Mar 2026-2207.5% -704.0 pp-1902.2 pp
INOInovio Pharmaceuticals, Inc.FY2025-132871.3% -81254.4 pp-130264.0 pp
VORVor Biopharma Inc.FY2025— ——
PEPGPepGen Inc.FY2025— ——
MOLNMolecular Partners AGFY2025— ——
NKTXNkarta, Inc.FY2025— ——
CRBPCorbus Pharmaceuticals Holdings, Inc.FY2025— ——
ABOSAcumen Pharmaceuticals, Inc.FY2025— ——
Peer median (excluding FATE) -741.3%-576.1 pp-65426.8 pp

Competitors are the stored peer set for FATE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue55.85M96.3M63.53M13.63M6.65M
Cost of Revenue5.85M13.76M157.19M118.53M12.9M
Gross Profit50M82.54M(93.65M)(104.9M)(6.26M)
Gross Margin89.5%85.7%-147.4%-769.6%-94.1%
Research & Development215.52M320.45M172.6M135M107.83M
Selling, General & Admin57.32M84.23M96.86M90.64M46.52M
Operating Expenses266.99M390.93M96.86M105.38M141.45M
Depreciation & Amortization5.85M13.76M18.28M18.96M9.3M
EBITDA(206.3M)(267.96M)(142.65M)(176.58M)(127.02M)
EBITDA Margin-369.4%-278.3%-224.5%-1295.4%-1911.2%
Operating Income(216.99M)(308.39M)(190.51M)(210.28M)(147.7M)
Operating Margin-388.6%-320.2%-299.9%-1542.6%-2222.4%
Interest Income1.31M5.84M17.19M17.29M11.05M
Interest Expense00000
Other Income / Expenses4.84M26.67M29.58M24.01M11.39M
Income Before Tax(212.15M)(281.72M)(160.93M)(186.26M)(136.32M)
Pre-Tax Margin-379.9%-292.5%-253.3%-1366.5%-2051.1%
Income Tax Expense00000
Net Income(212.15M)(281.72M)(160.93M)(186.26M)(136.32M)
Net Margin-379.9%-292.5%-253.3%-1366.5%-2051.1%
EPS (Basic)(2.24)(2.91)(1.64)(1.64)(1.15)
EPS (Diluted)(2.24)(2.91)(1.64)(1.64)(1.15)
Weighted Avg Shares94.75M96.83M98.41M113.69M118.79M
Weighted Avg Shares (Diluted)94.75M96.83M98.41M113.69M118.79M

Fate Therapeutics, Inc.

NASDAQ:FATE

Intrinsic Alpha fair value

Locked

Current Price

$1.02

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.